Impact of the selective A2(A)R and A2(B)R dual antagonist AB928/etrumadenant on CAR T cell function

BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy has been successfully translated to clinical practice for the treatment of B cell malignancies. The suppressive microenvironment of many malignancies is a bottleneck preventing treatment success of CAR T cells in a broader range of tumours....

Descripción completa

Detalles Bibliográficos
Autores principales: Seifert, Matthias, Benmebarek, Mohamed-Reda, Briukhovetska, Daria, Märkl, Florian, Dörr, Janina, Cadilha, Bruno L., Jobst, Jakob, Stock, Sophia, Andreu-Sanz, David, Lorenzini, Theo, Grünmeier, Ruth, Oner, Arman, Obeck, Hannah, Majed, Lina, Dhoqina, Dario, Feinendegen, Manouk, Gottschlich, Adrian, Zhang, Jin, Schindler, Ulrike, Endres, Stefan, Kobold, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726885/
https://www.ncbi.nlm.nih.gov/pubmed/36266575
http://dx.doi.org/10.1038/s41416-022-02013-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726885/
https://www.ncbi.nlm.nih.gov/pubmed/36266575
http://dx.doi.org/10.1038/s41416-022-02013-z

Ejemplares similares